WO2022225379A1

WO2022225379A1 - Device for treating overactive bladder

Info

Publication number: WO2022225379A1
Application number: PCT/KR2022/005876
Authority: WO
Inventors: 김승범
Original assignee: 김승범
Priority date: 2021-04-23
Filing date: 2022-04-25
Publication date: 2022-10-27
Also published as: KR20220146361A

Abstract

The present invention provides a device for treating an overactive bladder, comprising: a guide part which can be worn on a foot, and which includes a band part in the form of a vertically elongated band, and a marker positioned at one end of the band part, wherein the band part has a width of 2.5 cm, includes a first part positioned to wrap the ankle in the direction orthogonal to the ankle in a state in which the marker is positioned at the Sanyinjiao, a second part, which extends from the first part to the arch side of a foot and is positioned to wrap the heel while forming an angle of 60° with the first part, and a third part, which extends from the second part and is positioned to wrap the top part of the foot while forming a predetermined angle with the second part, and the Yon-gok is positioned between the second part and the third part; and a drug injection means for injecting a drug containing an anticholinergic into the part at which the marker is positioned and a predetermined region between the second part and the third part.

Description

Overactive Bladder Treatment Device

The present invention relates to a device for treating overactive bladder symptoms.

Overactive bladder refers to a symptom in which the bladder spontaneously contracts and urination occurs regardless of one's intentions, even though there is not enough urine accumulated in the bladder.

So-called urgency or urinary incontinence, this overactive neglect is a disease with a high frequency of occurrence in a significant number of male and female urinary tract.

The primary treatment for overactive bladder is behavioral therapy. Weight loss, physical therapy, smoking cessation, and limiting caffeine intake should be continued. Motivation to keep and not give up halfway is important. When behavioral therapy is not effective enough, oral drug therapy is used in combination, and it takes 6 to 8 weeks for the effect to appear.

Patients unsuccessful with oral medication seek other treatment options. A drug that blocks the secretion or action of the neurotransmitter acetylcholine is injected directly into the bladder.

According to the clinical results, when the drug is directly injected into the bladder as described above, it showed efficacy in 60 to 70% of patients who failed oral drug treatment. In particular, when administered to patients with symptoms of urine leakage 5.5 times a day, 20-30% of the patients showed a complete cure.

However, since the drug is directly injected into the bladder, it is invasive and places a great burden on the patient's body.

Patent Document 1 discloses a method of reducing invasion and maximizing effect by injecting a drug into a target site below the bladder midline.

In the case of Patent Document 1, although the injection site or site into the bladder is reduced. Still the same doesn't change the need to inject directly into the bladder

As a method for solving this problem, recently, a method of applying electrical stimulation to the tibial nerve connected to the bladder as a nerve on the side of the leg has been implemented. This method has the advantage that it is not invasive as much as inserting an electrode into the leg, but the effect is not large in that it gives only electrical stimulation to the nerve, and there is a problem that the effect is not continuous.

That is, there is a need for a non-invasive and effective treatment for overactive bladder, rather than an invasive act of injecting a drug directly into the bladder. There is a problem of side effects that occur when the drug is directly injected into the surrounding bone.

(Patent Document 1) KR 10-2019-0005149 A

Accordingly, the present invention has been devised to solve the problems of the prior art, and it is an object of the present invention to provide an apparatus for treating overactive bladder with excellent therapeutic effect while minimizing the burden on the patient's body.

In order to achieve the above object, the present invention provides an apparatus for treating overactive bladder, including a guide part that can be worn on the foot, an elongated band-shaped band part, and a marker positioned at one end of the band part, and the band part is a width of 2.5 cm, a first part positioned so as to be wound in a direction perpendicular to the ankle in a state in which the marker is positioned on the sameumgyohyeol, and extending from the first part to the arch side of the foot A second part positioned to wrap the heel at an angle of 60° with the part, and a third part extending from the second part and positioned to wind the instep while forming a predetermined angle with the second part, a guide part in which soft blood is located between the second part and the third part; and a drug injection means configured to inject a drug containing an anticholinergic into a portion where the marker is located and a predetermined region between the second portion and the third portion.

It is preferable that the marker is not located on the tibial nerve in a state where the marker is located on the sameumgyohyeol.

The portion between the second portion and the third portion is preferably a portion through which the tibial nerve and blood vessels do not pass.

The drug is preferably a drug containing botulinum toxin.

The drug injection means is inserted into the foot of the patient to be treated, so that the drug is injected; and a stopper protrudingly spaced apart from the front end of the needle by a predetermined distance.

The predetermined distance between the tip of the needle and the stopper is preferably 4 mm or more and 6 mm or less.

It is preferable to further include binding portions respectively positioned at both ends of the band portion.

According to the apparatus for treating overactive bladder according to the present invention, by injecting a drug into the area where the sameumgyohyeol and yeongokhyeol located in the vicinity of the tibial nerve extending from the bladder to the foot, the drug is injected directly into the bladder. It is non-invasive compared to the method of injecting the drug, and also has the advantage that a direct therapeutic effect can be obtained together by injecting the drug rather than simply electrical stimulation.

In addition, it is possible to grasp the vicinity of the sameumgyohyeol and yeongokhyeol to be injected, and it is possible to prevent side effects due to incorrect injection.

Figure 1 shows the tibial nerve extending from the bladder and passing through the foot, and the sameumgyohyeol and yeongokhyeol in the vicinity thereof.

Figure 2 shows a guide portion of the overactive bladder treatment apparatus according to an embodiment of the present invention.

3 is a schematic diagram of a drug injection means of an overactive bladder treatment device according to an embodiment of the present invention.

4 and 5 show a state in which the guide part of the overactive bladder treatment apparatus according to an embodiment of the present invention is worn on the feet.

The above objects, features and other advantages of the present invention will become more apparent by describing preferred embodiments of the present invention in detail with reference to the accompanying drawings. In this process, the thickness of the lines or the size of the components shown in the drawings may be exaggerated for clarity and convenience of explanation. In addition, the terms to be described later are terms defined in consideration of functions in the present invention, which may vary according to intentions or customs of users and operators. Therefore, definitions of these terms should be described based on the content throughout this specification.

In addition, the described embodiments are provided by way of example for the description of the invention, and do not limit the technical scope of the present invention.

Hereinafter, an overactive bladder treatment apparatus according to an embodiment of the present invention will be described in detail with reference to the accompanying drawings.

The device for treating overactive bladder according to an embodiment of the present invention is configured to inject a drug containing an anticholinergic or neurotoxin, which is a drug that blocks the secretion or action of acetylcholine, into the foot region of a subject for bladder treatment.

In addition, in the following description, Sameumgyohyeol (三陰交穴) and Yeongokhyeol (然谷穴) are acupoints called in oriental medicine, and their positions are known.

As shown in Fig. 1, the tibial nerve is a nerve located at the foot of the body and is connected to the bladder, and Sameumgyohyeol and Yeongokhyeol are located in the vicinity of the tibial nerve passing through the foot.

2 to 4, the configuration of the overactive bladder treatment device according to the present invention will be described in detail.

2 and 3 , the apparatus for treating overactive bladder according to an embodiment of the present invention includes a guide part 100 and a drug injection means 200 .

As shown in FIG. 2 , the guide part 100 includes a band part 110 , a marker 120 , and a binding part 130 .

The band unit 110 is configured in a band shape having a predetermined width. The band 110 is worn to be wrapped around the foot of the patient to be treated as being made in the form of a band.

The marker 120 is located at the end of one side in the longitudinal direction of the band unit 110 . The marker 120 is positioned so as to be distinguished from the band part 110 . For example, it may be made of a material or color different from that of the band unit 110 , but is not limited thereto, and the marker 120 may be easily identified on the band unit 110 .

Preferably, the marker 120 is made of a fabric of a different material or a mesh material of a different color, so that the drug injection by the drug injection means 200 to be described later is easy.

The marker 120 has a width of 1 cm in the longitudinal direction of the band unit 110, and thus, the position of the Sameumgyohyeol and its vicinity in the state where the guide unit 100 is worn on the foot is grasped.

At both ends of the band unit 110 in the longitudinal direction, each binding unit 130 is positioned so that the band unit 110 is fixed and worn around the foot.

2, the binding part 130 may be provided with a Velcro material on both sides of the band part 110. In this case, each binding part 130 is located at one end of one side of the band part and the other end of the other side, respectively. can

However, the configuration of the binding part 130 is not limited thereto, and by being configured with a binding means such as a button, a hook or an adhesive part coated with an adhesive, the band part 110 is fixed in a wound state around the foot. It should be configuration.

The band unit 110 is wound around the instep, heel, and ankle of the patient's foot so that the guide unit 100 is positioned on the foot.

The width of the band portion 110 is configured to be 2.5 cm. By making the width of the band 110 in this way, the position of the vicinity of the sameumgyohyeol and yeongokhyeol to be injected with the drug in the state where the band 110 is located on the foot can be grasped.

As shown in FIG. 4 , the guide part 100 is worn to be wound around the instep, heel and ankle of the patient's foot by the band part 110 , and in this state, the first part 111 , the second part It is divided into a part 112 and a third part 113 .

The first part 111 is positioned to wind the ankle region, the second part 112 is positioned to wind the heel region, and the third part 113 is positioned to wind the instep, which will be described later in detail.

The drug injection means 200 is configured to inject the drug into a specific area of the foot where the guide part 100 is located, that is, a predetermined area near the Sameumgyohyeol or Yeongokhyeol.

As shown in FIG. 3 , the drug injection means 200 includes a needle 210 , a drug receiving part 230 and a connecting tube 220 .

The needle 210 is inserted into a predetermined area in the vicinity of the sameumgyohyeol or yeongokhyeol in the shape of a needle with a sharp tip.

In addition, a stopper 211 that is spaced apart from the tip of the needle 210 by a predetermined distance and protrudes may be formed.

By positioning the stopper 211, the needle 210 is prevented from being inserted into the patient's foot by a predetermined depth or more. The position of the stopper 211 is preferably 4mm or more and 6mm or less at which the tip of the needle 210 and the stopper 211 are spaced apart.

The drug receiving unit 230 accommodates a drug containing an anticholinergic or neurotoxin, which is a drug that blocks the secretion or action of acetylcholine.

The neurotoxin included in the drug accommodated in the drug receiving unit 230 may be botulinum toxin. As the botulinum toxin paralyzes the nervous tissue, the muscles connected to it also paralyze. A drug containing botulinum toxin may use Botox (Botox ^® , a registered trademark of Allergant).

The needle 210 and the drug accommodating part 230 are connected by a connection tube 220, and the drug accommodated in the drug accommodating part 230 passes through the connection tube 220 and is injected into a desired portion through the needle 210. Although not shown, a pump for supplying the drug accommodated in the drug receiving unit 230 to the needle 210 side may be provided.

In addition, of course, the drug injection means 200 may be configured as a syringe equipped with a needle 210 that is generally used.

Next, a process of injecting a drug into a treatment target patient using the overactive bladder treatment apparatus according to an embodiment of the present invention will be described with further reference to FIGS. 4 and 5 .

The foot part is a region through which the tibial nerve connected to the bladder passes, and the drug should be injected in the vicinity of the tibial nerve, but not directly into the nerve, and should not be injected directly into the bone or blood vessel, but should be injected near the nerve.

When the posterior tibial nerve is injured, it is impossible to bend the foot toward the sole of the foot and the sensation of the sole of the foot disappears. Therefore, it is necessary to prevent drug injection into the nerve itself.

First, the guide unit 100 is worn on the foot of the patient to be treated. The guide unit 100 is worn to be wound around the ankle, instep, and heel region of the patient to be treated.

Specifically, in a state in which the marker 120 located on one side of the band unit 110 is located on the sameumgyohyeol but not located on the tibial nerve so that it is visible from the outside (refer to FIG. 5), one side of the band unit 110 is perpendicular to the ankle in the direction orthogonal to the ankle. is positioned to wind Specifically, it is positioned so that the shortest distance from the top of the peach bone to the band part 110 is 4.05 cm to 4.95 cm, more specifically 4.5 cm away from the ankle.

In this way, the portion where the band portion 110 is positioned to wrap the ankle becomes the first portion. The marker 120 located on the first part 111 is located on the sameumgyohyeol, but so that it is not located on the tibial nerve, the end of one side of the band 100 starts from the posterior tibia and the ankle It is preferable to wind up.

The band part 110 extends from the first part 111 and forms an angle of 60° with the first part 111 and extends to the arch side of the foot and is positioned to wind the heel side, and in this way, the band part 110 is A portion positioned to wind the heel portion becomes the second portion.

And, the band part 110 extends from the second part 112, and forms a predetermined angle with the second part 112 and is positioned to wind the instep side, and in this way, the band part 110 is positioned to wind the instep part. The portion to be the third part 113 .

As described above, the band part 110 is positioned on the foot by the first part 111 , the second part 112 and the third part 113 , and both ends of the band part 110 are connected by the binding part 130 . By binding, the guide part 100 may be worn on the foot.

In this state, a drug containing an anticholinergic or a drug containing a neurotoxin is injected into a predetermined region near Sameumgyohyeol or Yeongokhyeol by the drug injection means 200 .

At this time, as shown in FIG. 5 , the positions of Sameumgyohyeol and Yeongokhyeol are grasped by the marker 120 and each

part

111 , 112 , 113 of the band part 110 .

Specifically, by the marker 120 located in the first portion 111, the position of the sameumgyohyeol located between the tibia and the tibial nerve and its vicinity is grasped.

And, by the second part 112, the tibial nerve is covered from the ankle side through the heel part to the sole side, and the soft blood is placed between the second part and the third part, so that the soft blood and a predetermined amount in the vicinity thereof. The region is identified, and through the drug injection means 200, the location of the sameumgyohyeol and yeongokhyeol, that is, the drug is injected near the tibial nerve rather than directly into the tibial nerve passing through the ankle and sole.

As described above, the band 110 has a width of 2.5 cm. If the width is narrower than 2.5 cm, it may not completely cover the tibial nerve in the second part, and if the width is wider than 2.5 cm, the second part and the second part. The width of the overlapping part of the three parts is widened so that it is possible to cover the part where the calcaneus or navicular bone is located.

In this case, the drug may be injected directly into the tibial nerve, calcaneus, or scaphoid bone, which may cause a problem. location is determined.

Accordingly, the drug is prevented from being directly injected into the tibial nerve or bone, and can be injected into a predetermined area near the triumium or yeongokhyeol near the tibial nerve.

When the drug is injected by the drug injection means 200, the needle 210 is inserted into the patient's sameumgyohyeol or yeongokhyeol. do.

It is possible to inject the drug by avoiding the tibial nerve, scaphoid bone, tibia, etc. by the band part 110, but it is undesirable to inject the drug because the needle 210 is inserted too deeply, so the needle by the stopper 211 210 is inserted into the patient's foot more than a predetermined depth is prevented from injecting the drug.

Then, the drug accommodated in the drug receiving unit 230 passes through the connection tube 220 and is injected into the patient's foot through the needle 210 to express the effect of the drug.

By injecting an anticholinergic agent or botulinum toxin near the tibial nerve connected to the bladder, it is effective by suppressing the contraction of the bladder that is not related to the doctor due to overactive bladder symptoms.

As such, according to the device for treating overactive bladder according to the present invention, by injecting the drug into the sameumgyohyeol and yeongokhyeol located in the vicinity of the tibial nerve extending from the bladder to the foot, it is non-invasive compared to the method of directly injecting the drug into the bladder. , and also has the advantage of being able to obtain a direct therapeutic effect by injecting a drug rather than simply electrical stimulation.

In addition, it is possible to determine the location of the sameumgyohyeol and yeongokhyeol where the drug should be injected, thereby preventing side effects due to incorrect injection.

Although preferred embodiments of the present invention have been described above, the present invention is not limited to the specific embodiments described above. That is, a person of ordinary skill in the art to which the present invention pertains can make numerous changes and modifications to the present invention without departing from the spirit and scope of the appended claims, and all such appropriate changes and modifications are possible. Equivalents are to be considered as falling within the scope of the present invention.

(Explanation of symbols)

110: band unit

120: marker

130: binding unit

200: drug injection means

210: needle

211: stopper

220: connection tube

230: drug receiving unit

Claims

A device for treating overactive bladder comprising:

As a guide part 100 that can be worn on the foot, it includes a band part 110 in the form of an elongated band, and a marker 120 located at one end of the band part 110 ,

The band part has a width of 2.5 cm, and the first part 111, the first part ( 111) extending toward the arch of the foot and forming an angle of 60° with the first part 111 and a second part 112 positioned to wrap the heel, and extending from the second part 112 to the second and a third part 113 positioned to wind the instep while forming a predetermined angle with the part 112 , and between the second part 112 and the third part 113 . The guide unit 100 is located; and

a drug injection means 200 configured to inject a drug containing an anticholinergic into a portion where the marker 120 is located and a predetermined region between the second portion 112 and the third portion 113; containing,

Device.
According to claim 1,

In a state in which the marker 120 is located on the trium, the marker 120 is not located on the tibial nerve,

Device.
3. The method of claim 2,

The portion between the second portion 112 and the third portion 113 is a portion through which the tibial nerve and blood vessels do not pass,

Device.
The method of claim 1,

The drug is a drug containing botulinum toxin,

Device.
The method of claim 1,

The drug injection means 200 is inserted into the foot of the patient to be treated, the needle 210 to inject the drug; and

Including;;

Device.
6. The method of claim 5,

The predetermined distance between the front end of the needle 219 and the stopper 211 is 4 mm or more and 6 mm or less,

Device.
The method of claim 1,

Further comprising binding portions 130 respectively positioned at both ends of the band portion 110,

Device.